support@purchasepeptideseco.com

ACP-105

Molecular formula: C16-H19-CIN2-O

Molar Mass: 290,791 g/mol

PubChem (CID): 45486107

Purity (HPLC): 98,6%

ACP-105 is a non-steroidal medicine that belongs to a class of selective androgen receptor modulators (SARM). The medicine was developed by Acadia Pharmaceuticals, a Swedish company. SARM is a new class of medicines developed for the treatment of various diseases, such as muscle wasting and osteoporosis; they have fewer adverse side effects compared to current methods of treatment based on testosterone replacement therapy.

Preclinical studies of the medicine showed its high efficacy, the same as in testosterone, however, without any adverse interaction with other hormone (estrogen) receptors. ACP-105 has a powerful anabolic effect on muscle and bone tissue with minimal impact on the prostate.

The studies showed that a relatively low concentration of ACP-105 binds to the androgen receptor better than, for example, dihydrotestosterone (DHT).

ACP-105 is administered orally and has a high level of bioavailability.

ACP-105 has following effects:

  • It increases muscle mass.
  • It increases muscle density.
  • It increases tolerance.
  • It reduces fatty deposits.
  • It strengthens bone tissue.
  • It rapidly recovers muscle fibers.
  • It improves blood circulation.

The recommended dosage is 10-15 mg per day. The medicine is taken once a day in the morning. The medicine has an effect on both males and females. The medicine doesn’t cause a virilization phenomenon – this is a great advantage for women.

ACP-105 is non-toxic to the liver; it doesn’t affect the endocrine profile, doesn’t adversely affect the reproductive system and doesn’t cause androgenic side effects. The medicine is safer and more effective than traditional prohormones and anabolic steroids.

For research purposes only.